Medical/Pharmaceuticals

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling$30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital...

2022-01-27 22:10 2845

FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion

SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation toDZD9008 (Sunvozertinib) for the treatment of patients with locally advanced or metasta...

2022-01-27 21:15 4877

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

DURHAM, N.C. and BEIJING, Jan. 27, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public healt...

2022-01-27 21:00 5834

Exyte Closes 2021 with Record Order Intake

- Order intake FY 2021 of over €8 billion, more than doubling YOY - Semiconductor and battery boom are main drivers for increased order intake - Outlook continues to be very positive STUTTGART, Germany, Jan. 27, 2022 /PRNewswire/ -- Exyte, a global leader in the design, engineering, and delivery ...

2022-01-27 20:53 4547

Mentice's CEO Goran Malmberg to present the company's Year-end Report Q4 2021 at a webcast conference call on February 3rd at 9:30 CET

STOCKHOLM, Jan. 27, 2022 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its year-end report via a webcast conference call with the opportunity for interested parties to ask questions to CEOGoran Malmberg and CFOGunilla Andersson. To register for the presentation o...

2022-01-27 17:42 2427

ClinChoice Looks to Advance Global Safety Operations with LifeSphere MultiVigilance

MIAMI, Jan. 27, 2022 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end technology platformLifeSphere®, today announced ClinChoice has enlisted the LifeSphere MultiVigilance solution to manage pharmacovigilance activ...

2022-01-27 09:00 4181

iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022

SEOUL, South Korea, Jan. 27, 2022 /PRNewswire/ -- iMediSync, A biotech startup company fromSeoul, South Korea, successfully debuted at CES 2022 to introduce the new trend of digital healthcare under their motto – Overcome Mental Pandemic in just 10 Min.

2022-01-27 08:00 5744

TriNetX Announces the Appointment of Shogo Wakabayashi as Japan Country Manager

CAMBRIDGE, Mass., Jan. 27, 2022 /PRNewswire/ -- TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, has announced thatShogo Wakabayashi has joined the company as Country Manager forJapan. Wakabayashi, a business leade...

2022-01-27 08:00 3011

I Peace's Cell Manufacturing Facility "Peace Engine Kyoto" now registered as U.S. FDA Drug Establishment

PALO ALTO, Calif., Jan. 26, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up, announced that its cell manufacturing facility is now listed on the FDA "Drug Establishments Current Registration Site." The registration recognizes I Peace's cell manufacturing f...

2022-01-27 01:00 2171

iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022

SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- iMediSync, A biotech startup company fromSeoul, South Korea, successfully debuted at CES 2022 to introduce the new trend of digital healthcare under their motto – Overcome Mental Pandemic in just 10 Min.

2022-01-26 22:00 4433

China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price Requirement

HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on J...

2022-01-26 21:00 4853

Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)

NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has entered into a Global License Agreement with Xiamen Biotime Biot...

2022-01-26 21:00 2402

Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the Investigational New Drug (IND) application of its second fatty acid synthase (F...

2022-01-26 19:00 4405

Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control

HONG KONG and SINGAPORE, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific International LTD  (PHASE Scientific), today announced that its INDICAID™ COVID-19 Rapid Antigen Test (INDICAID™) has received authorisation from the Health Sciences Authority ofSingapore, wh...

2022-01-26 17:18 3947

Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control

HONG KONG, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific International LTD  (PHASE Scientific), today announced that its  INDICAID™ COVID-19 Rapid Antigen Test (INDICAID™) has received authorisation from the Health Sciences Authority ofSingapore, which can make i...

2022-01-26 17:15 3662

Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve

HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity interest in Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral a...

2022-01-26 14:28 6315

RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome

YANTAI, China, Jan. 26, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...

2022-01-26 10:52 4764

GenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio

SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- GenScript ProBio, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced onJanuary 26th, 2022 that it entered into a contract with InnoBation Bio to develop and manufacture clinical trial sample substances...

2022-01-26 09:00 3677

Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in Androgen Alopecia

SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for phase II study to evaluate HMI-115, a ...

2022-01-26 08:00 3614

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients

COPENHAGEN, Denmark, Jan. 25, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the company's first development candidate targeting E. coli i...

2022-01-25 22:42 2487
1 ... 604605606607608609610 ... 644

Week's Top Stories